INmune Bio Inc. entered into a securities purchase agreement with a single institutional investor to raise approximately $4.5 million in gross proceeds through a registered direct offering and a concurrent private placement.
Key Details
- Offering Terms: The company agreed to sell 3,000,000 shares of its common stock at a purchase price of $1.50 per share in the registered direct offering.
- Warrants: In the concurrent private placement, the investor will receive warrants to purchase up to 3,000,000 shares of common stock. These warrants have an exercise price of $1.65 per share, become exercisable on April 27, 2027, and expire on April 27, 2032.
- Financials & Closing: The offering is expected to generate gross proceeds of $4.5 million before deducting placement agent fees and other expenses. The transaction is anticipated to close on or about October 29, 2026.